A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors.
View / Open Files
Authors
Kalra, Rajkumar S
Soman, Gaurav S
Parab, Pradeep B
Mali, Avinash M
Naik, Rutika R
Kamble, Swapnil C
Dhanjal, Jaspreet K
Bapat, Sharmila A
Publication Date
2022-01Journal Title
Transl Oncol
ISSN
1936-5233
Publisher
Elsevier BV
Volume
15
Issue
1
Number
ARTN 101257
Pages
101257
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Kalra, R. S., Soman, G. S., Parab, P. B., Mali, A. M., Varankar, S., Naik, R. R., Kamble, S. C., et al. (2022). A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors.. Transl Oncol, 15 (1. ARTN 101257), 101257. https://doi.org/10.1016/j.tranon.2021.101257
Abstract
The involvement of cancer stem cells (CSCs) in driving tumor dormancy and drug resistance is well established. Most therapeutic regimens however are ineffective in targeting these regenerative populations. We report the development and evaluation of a monoclonal antibody, mAb150, which targets the metastasis associated antigen, Annexin A2 (AnxA2) through recognition of a N-terminal epitope. Treatment with mAb150 potentiated re-entry of CSCs into the cell cycle that perturbed tumor dormancy and facilitated targeting of CSCs as was validated by in vitro and in vivo assays. Epigenetic potentiation further improved mAb150 efficacy in achieving total tumor regression by targeting regenerative populations to achieve tumor regression, specifically in high-grade serous ovarian adenocarcinoma.
Keywords
Active cooperative cell migration, Annexin A2, Cancer stem cells, Epigenetic potentiation, Monoclonal antibody, Progenitors
Identifiers
External DOI: https://doi.org/10.1016/j.tranon.2021.101257
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332265
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.